Trial Outcomes & Findings for Sodium Nitroprusside in Early Course Schizophrenia (NCT NCT04986072)
NCT ID: NCT04986072
Last Updated: 2025-12-30
Results Overview
Comparing total, positive, and negative scores between SNP and Placebo
Recruitment status
TERMINATED
Study phase
PHASE2
Target enrollment
1 participants
Primary outcome timeframe
Measured at hour 2
Results posted on
2025-12-30
Participant Flow
study terminated sue to low recruitment
Participant milestones
| Measure |
Sodium Nitroprusside Arm
Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
Sodium Nitroprusside: Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
|
Placebo Arm
5% Dextrose (0.5 μg/kg/min) for 4 hours
5% Dextrose solution: Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
1
|
|
Overall Study
COMPLETED
|
0
|
1
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Sodium Nitroprusside in Early Course Schizophrenia
Baseline characteristics by cohort
| Measure |
Sodium Nitroprusside Arm
Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours
Sodium Nitroprusside: Half of participants will receive Intravenous Sodium Nitroprusside (0.5 μg/kg/min) for 4 hours.
|
Placebo Arm
n=1 Participants
5% Dextrose (0.5 μg/kg/min) for 4 hours
5% Dextrose solution: Half of participants will receive intravenous 5% Dextrose solution for 4 hours.
|
Total
n=1 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Customized
Due to privacy concerns of single participant, data will not be shown for this outcome
|
—
|
NA Participants
n=6 Participants
|
NA Participants
n=9 Participants
|
|
Sex/Gender, Customized
Due to privacy concerns of single participant, data will not be shown for this outcome
|
—
|
NA Participants
n=6 Participants
|
NA Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
—
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
—
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
—
|
1 Participants
n=6 Participants
|
1 Participants
n=9 Participants
|
|
Region of Enrollment
United States
|
—
|
1 participants
n=6 Participants
|
1 participants
n=9 Participants
|
|
PANSS Total Score
|
—
|
NA score on scale
n=6 Participants
|
0 score on scale
n=9 Participants
|
PRIMARY outcome
Timeframe: Measured at hour 2Population: Due to privacy concerns of single participant, data will not be shown for this outcome
Comparing total, positive, and negative scores between SNP and Placebo
Outcome measures
Outcome data not reported
Adverse Events
Sodium Nitroprusside Arm
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Placebo Arm
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Paulo Lizano MD, PhD
University of Rochester Medical Center
Phone: (201) 776-6708
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place